These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26516934)

  • 1. A New Immunotherapy Drug Creates a Watershed for the Surgical Pathologist's Role in Patient Care.
    Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2015 Nov; 139(11):1329. PubMed ID: 26516934
    [No Abstract]   [Full Text] [Related]  

  • 2. First-Line Immune Therapy-Implications for Pathologists.
    Miller RA; Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2016 Aug; 140(8):739-40. PubMed ID: 27472228
    [No Abstract]   [Full Text] [Related]  

  • 3. PD-1-targeted immunotherapy: recent clinical findings.
    Brahmer JR
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
    [No Abstract]   [Full Text] [Related]  

  • 4. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression as a potential predictive biomarker.
    Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
    Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
    [No Abstract]   [Full Text] [Related]  

  • 7. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
    Leventakos K; Mansfield AS
    BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status.
    Chandrakanth MV; Noronha V; Joshi A; Patil V; Mahajan A; Prabhash K
    Indian J Cancer; 2017; 54(1):55-56. PubMed ID: 29199664
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immuno-Oncology therapeutic principles in lung and renal cell carcinoma].
    Wolf J; Grünwald V
    Oncol Res Treat; 2014; 37 Suppl 4():10-3. PubMed ID: 25301191
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
    Kerr KM; Nicolson MC
    Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Advanced Lung Cancer.
    Asmar R; Rizvi NA
    Cancer J; 2015; 21(5):383-91. PubMed ID: 26389763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted programmed cell death in lung cancer treatment.
    Zimmerman MP; Mehr SR
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E3. PubMed ID: 25618630
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
    He J; Hu Y; Hu M; Li B
    Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
    Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
    Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective.
    Bernicker E
    Arch Pathol Lab Med; 2016 Mar; 140(3):245-8. PubMed ID: 26927719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S19-28. PubMed ID: 26477471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.
    Rijavec E; Genova C; Alama A; Barletta G; Sini C; Pronzato P; Coco S; Dal Bello MG; Savarino G; Truini A; Boccardo F; Grossi F
    Future Oncol; 2014 Jan; 10(1):79-90. PubMed ID: 24328411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer.
    Shi H; Guo J; Li C; Wang Z
    Drug Des Devel Ther; 2015; 9():4989-96. PubMed ID: 26357465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.